Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (Aβ) peptide aggregation for treating Alzheimer's disease

Zheng Li Zhou, Yih Ho, Hsuan Liang Liu, Pavadai Elumalai, Wei Hsi Chen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A non-peptide inhibitor that is metabolically stable, orally active and capable of crossing the blood-brain barrier has been a popular option for treating Alzheimer's disease (AD). To identify novel non-peptide inhibitors for AD drug development, a structure-based pharmacophore model (SBPM) was developed using the representative docked conformation of the recently discovered peptide inhibitor PGKLVYA in the potential binding site on the Aβ(17-42) protofibril. The best SBPM, consisting of two hydrophobic, one hydrogen bond donor, and one positive ionisable feature, was further validated using ligand pharmacophore mapping studies. The well-validated SBPM was then used as the 3D query in virtual screening to identify potential hits from the National Cancer Institute database. These hits were subsequently filtered by toxicity prediction and molecular docking, and their binding stabilities and affinities were validated by 20-ns molecular dynamics simulations and molecular mechanics Poisson-Boltzmann surface area analysis, respectively. Finally, two Hits (NSC35984 and NSC102747) were identified as potential leads, which exhibited higher binding stability and affinity towards Aβ compared with PGKVYA. Our results also suggest that these two Hits have the ability to prevent Aβ adopting toxic β-sheet structures, and can be easily synthesised and have structural novelty, indicating that they are promising candidates for treating AD.

Original languageEnglish
Pages (from-to)622-632
Number of pages11
JournalMolecular Simulation
Volume41
Issue number8
DOIs
Publication statusPublished - May 24 2015

Fingerprint

Alzheimer's Disease
Hits
Amyloid
Peptides
inhibitors
Inhibitor
peptides
Aggregation
Agglomeration
affinity
blood-brain barrier
Affine transformation
Molecular mechanics
Poisons
Binding sites
Molecular Docking
Virtual Screening
toxicity
Molecular Mechanics
Toxicity

Keywords

  • Alzheimer's disease
  • amyloid-beta
  • non-peptide inhibitor
  • structure-based pharmacophore
  • virtual screening

ASJC Scopus subject areas

  • Condensed Matter Physics
  • Modelling and Simulation
  • Chemistry(all)
  • Chemical Engineering(all)
  • Materials Science(all)
  • Information Systems

Cite this

Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (Aβ) peptide aggregation for treating Alzheimer's disease. / Zhou, Zheng Li; Ho, Yih; Liu, Hsuan Liang; Elumalai, Pavadai; Chen, Wei Hsi.

In: Molecular Simulation, Vol. 41, No. 8, 24.05.2015, p. 622-632.

Research output: Contribution to journalArticle

Zhou, Zheng Li ; Ho, Yih ; Liu, Hsuan Liang ; Elumalai, Pavadai ; Chen, Wei Hsi. / Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (Aβ) peptide aggregation for treating Alzheimer's disease. In: Molecular Simulation. 2015 ; Vol. 41, No. 8. pp. 622-632.
@article{6998862a2ae241c9b223535c4e09278d,
title = "Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (Aβ) peptide aggregation for treating Alzheimer's disease",
abstract = "A non-peptide inhibitor that is metabolically stable, orally active and capable of crossing the blood-brain barrier has been a popular option for treating Alzheimer's disease (AD). To identify novel non-peptide inhibitors for AD drug development, a structure-based pharmacophore model (SBPM) was developed using the representative docked conformation of the recently discovered peptide inhibitor PGKLVYA in the potential binding site on the Aβ(17-42) protofibril. The best SBPM, consisting of two hydrophobic, one hydrogen bond donor, and one positive ionisable feature, was further validated using ligand pharmacophore mapping studies. The well-validated SBPM was then used as the 3D query in virtual screening to identify potential hits from the National Cancer Institute database. These hits were subsequently filtered by toxicity prediction and molecular docking, and their binding stabilities and affinities were validated by 20-ns molecular dynamics simulations and molecular mechanics Poisson-Boltzmann surface area analysis, respectively. Finally, two Hits (NSC35984 and NSC102747) were identified as potential leads, which exhibited higher binding stability and affinity towards Aβ compared with PGKVYA. Our results also suggest that these two Hits have the ability to prevent Aβ adopting toxic β-sheet structures, and can be easily synthesised and have structural novelty, indicating that they are promising candidates for treating AD.",
keywords = "Alzheimer's disease, amyloid-beta, non-peptide inhibitor, structure-based pharmacophore, virtual screening",
author = "Zhou, {Zheng Li} and Yih Ho and Liu, {Hsuan Liang} and Pavadai Elumalai and Chen, {Wei Hsi}",
year = "2015",
month = "5",
day = "24",
doi = "10.1080/08927022.2014.910600",
language = "English",
volume = "41",
pages = "622--632",
journal = "Molecular Simulation",
issn = "0892-7022",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Computer-aided discovery of novel non-peptide inhibitors against amyloid-beta (Aβ) peptide aggregation for treating Alzheimer's disease

AU - Zhou, Zheng Li

AU - Ho, Yih

AU - Liu, Hsuan Liang

AU - Elumalai, Pavadai

AU - Chen, Wei Hsi

PY - 2015/5/24

Y1 - 2015/5/24

N2 - A non-peptide inhibitor that is metabolically stable, orally active and capable of crossing the blood-brain barrier has been a popular option for treating Alzheimer's disease (AD). To identify novel non-peptide inhibitors for AD drug development, a structure-based pharmacophore model (SBPM) was developed using the representative docked conformation of the recently discovered peptide inhibitor PGKLVYA in the potential binding site on the Aβ(17-42) protofibril. The best SBPM, consisting of two hydrophobic, one hydrogen bond donor, and one positive ionisable feature, was further validated using ligand pharmacophore mapping studies. The well-validated SBPM was then used as the 3D query in virtual screening to identify potential hits from the National Cancer Institute database. These hits were subsequently filtered by toxicity prediction and molecular docking, and their binding stabilities and affinities were validated by 20-ns molecular dynamics simulations and molecular mechanics Poisson-Boltzmann surface area analysis, respectively. Finally, two Hits (NSC35984 and NSC102747) were identified as potential leads, which exhibited higher binding stability and affinity towards Aβ compared with PGKVYA. Our results also suggest that these two Hits have the ability to prevent Aβ adopting toxic β-sheet structures, and can be easily synthesised and have structural novelty, indicating that they are promising candidates for treating AD.

AB - A non-peptide inhibitor that is metabolically stable, orally active and capable of crossing the blood-brain barrier has been a popular option for treating Alzheimer's disease (AD). To identify novel non-peptide inhibitors for AD drug development, a structure-based pharmacophore model (SBPM) was developed using the representative docked conformation of the recently discovered peptide inhibitor PGKLVYA in the potential binding site on the Aβ(17-42) protofibril. The best SBPM, consisting of two hydrophobic, one hydrogen bond donor, and one positive ionisable feature, was further validated using ligand pharmacophore mapping studies. The well-validated SBPM was then used as the 3D query in virtual screening to identify potential hits from the National Cancer Institute database. These hits were subsequently filtered by toxicity prediction and molecular docking, and their binding stabilities and affinities were validated by 20-ns molecular dynamics simulations and molecular mechanics Poisson-Boltzmann surface area analysis, respectively. Finally, two Hits (NSC35984 and NSC102747) were identified as potential leads, which exhibited higher binding stability and affinity towards Aβ compared with PGKVYA. Our results also suggest that these two Hits have the ability to prevent Aβ adopting toxic β-sheet structures, and can be easily synthesised and have structural novelty, indicating that they are promising candidates for treating AD.

KW - Alzheimer's disease

KW - amyloid-beta

KW - non-peptide inhibitor

KW - structure-based pharmacophore

KW - virtual screening

UR - http://www.scopus.com/inward/record.url?scp=84925643657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925643657&partnerID=8YFLogxK

U2 - 10.1080/08927022.2014.910600

DO - 10.1080/08927022.2014.910600

M3 - Article

AN - SCOPUS:84925643657

VL - 41

SP - 622

EP - 632

JO - Molecular Simulation

JF - Molecular Simulation

SN - 0892-7022

IS - 8

ER -